Bioavailability and Bioequivalence

Challenges in Drug Development

Considerable challenges in drug development, particularly in the face of further organizational changes slated for OGD. A range of legislative and regulatory actions have facilitated consumer access to safe, high-quality generic products, although manufacturing lapses and product quality problems have created critical shortages in important medicines, casting a shadow over the industry's success.

In 2012 the global market for drug development and services reached $3.5 billion. This market is reached $4.5 billion in 2013 and expected to reach 11.7 billion in 2018, a compound annual growth rate (CAGR) of 21.2%.